



TGF-βRII Knock-Down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727

Vincent Drubay, Nicolas Skrypek, Lucie Cordiez, Romain Vasseur, Céline Schulz, Nihad Boukrout, Belinda Duchêne, Lucie Coppin, Isabelle Van Seuningen and Nicolas Jonckheere



Supplementary Material





Figure S1. TGF-βRII knockdown promotes c-Jun S-63 phosphorylation in CAPAN-2 cells. (**A**) c-Jun, phospho-S63 c-Jun and β-actin expression was analyzed by western blotting. Bands intensities were quantified by densitometry and ratios (KD vs. NT or treated/untreated) are indicated in the graphs. Expression in NT (for TGF-βRIIKD) or untreated (for gemcitabine/TGF-β) cells was arbitrarily set to 1. (**B**) IHC analysis of c-Jun on extracted xenografted NT and TGF-βRIIKD tumors. (**C**) IHC staining was scored in NT and TGF-βRIIKD xenografted tumors that were treated with gemcitabine or PBS. * p < 0.05 indicate statistical significance of TGF-βRII-KD compared with the NT control.



Figure S2. TGF- β RII knockdown promotes partial EMT-like phenotype. IHC analysis of E-cadherin and vimentin on extracted xenografted NT and TGF- β RIIKD tumors. IHC staining was scored in NT and TGF- β RIIKD xenografted tumors that were treated with gencitabine or PBS. *p < 0.05, **p < 0.01 indicate statistical significance of TGF- β RII-KD compared with the NT control.